||
2023年1月16日,我院药事管理与临床药学系史录文/管晓东团队在肿瘤学权威期刊自然·综述系列Nature Reviews Clinical Oncology 在线发表了题为“Newly approved cancer drugs in China — innovation and clinical benefit”的评论文章。该文从作用机制、治疗需求与临床获益三个维度系统评价了2005-2021年中国获批上市抗肿瘤新药的创新性及临床价值。
https://www.ebiotrade.com/newsf/2023-1/20230119065209868.htm
http://www.pubmedplus.cn/P/SearchQuickResult?wd=12e63dd5-e891-49cb-a11d-4f65d9317b07
01. | Antineoplastic Agents | 193 篇 | 100.000% |
02. | Retrospective Studies | 193 篇 | 100.000% |
03. | Treatment Outcome | 193 篇 | 100.000% |
04. | Humans | 190 篇 | 98.446% |
05. | Female | 169 篇 | 87.565% |
06. | Male | 156 篇 | 80.829% |
07. | Middle Aged | 150 篇 | 77.720% |
08. | Aged | 143 篇 | 74.093% |
09. | Adult | 115 篇 | 59.585% |
10. | Aged, 80 and over | 65 篇 | 33.679% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-7-26 22:20
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社